NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT05886049 2026-03-18
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06222580 2026-03-13
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06575296 2026-03-05
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT06177067 2026-03-04
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06284486 2026-02-25
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06229912 2026-02-19
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07211958 2026-02-04
REVEAL-ND NPM1
Syndax Pharmaceuticals
Phase 3 Recruiting
NCT07356154 2026-01-21
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06313437 2025-03-27
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting